Highlights and Quick Summary
- Capex/Depreciation for the quarter ending June 30, 2023 was -0.3 (a -29.51% decrease compared to previous quarter)
- Year-over-year quarterly Capex/Depreciation decreased by -64.2%
- Annual Capex/Depreciation for 2022 was -0.93 (a -46.94% decrease from previous year)
- Annual Capex/Depreciation for 2021 was -1.76 (a 47.23% increase from previous year)
- Annual Capex/Depreciation for 2020 was -1.19 (a 56.34% increase from previous year)
- Twelve month Capex/Depreciation ending June 30, 2023 was -0.54 (a -17.85% decrease compared to previous quarter)
- Twelve month trailing Capex/Depreciation decreased by -45.53% year-over-year
Trailing Capex/Depreciation for the last four month:
30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
---|---|---|---|
-0.54 | -0.65 | -0.79 | -0.99 |
Visit stockrow.com/EBS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Capex/Depreciation of Emergent Biosolutions Inc.
Most recent Capex/Depreciationof EBS including historical data for past 10 years.Interactive Chart of Capex/Depreciation of Emergent Biosolutions Inc.
Emergent Biosolutions Inc. Capex/Depreciation for the past 10 Years (both Annual and Quarterly)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2023 | -0.3 | -0.42 | – | – | – |
2022 | -1.24 | -0.84 | -0.71 | -1.01 | -0.93 |
2021 | -1.55 | -1.63 | -1.96 | -1.89 | -1.76 |
2020 | -1.2 | -1.54 | -1.19 | -0.84 | -1.19 |
2019 | -1.26 | -0.54 | -0.48 | -0.78 | -0.76 |
2018 | -0.8 | -2.1 | -0.89 | -0.94 | -1.1 |
2017 | -0.86 | -1.3 | -0.94 | -2.0 | -1.24 |
2016 | -1.99 | -1.64 | -2.36 | -2.06 | -1.99 |
2015 | -1.18 | -1.63 | -1.21 | -1.06 | -1.27 |
2014 | -1.97 | -0.58 | -0.57 | -0.67 | -0.95 |
2013 | -1.4 | -3.92 | -1.53 | -1.84 | -2.22 |
2012 | -3.67 | -3.62 | – | – | -3.76 |
Business Profile of Emergent Biosolutions Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic